Immunic, Inc. Common Stock
IMUX
IMUX: Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
moreShow IMUX Financials
Recent trades of IMUX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by IMUX's directors and management
Government lobbying spending instances
-
$10,000 Jan 20, 2022 Issue: None
-
$20,000 Jan 20, 2022 Issue: None
-
$10,000 Oct 20, 2021 Issue: None
-
$20,000 Oct 20, 2021 Issue: None
-
$20,000 Jul 20, 2021 Issue: None
-
$20,000 Apr 20, 2021 Issue: None
-
$20,000 Jan 20, 2021 Issue: None
-
$10,000 Jul 20, 2020 Issue: Health Issues Medical/Disease Research/Clinical Labs Science/Technology
-
$10,000 Jul 17, 2020 Issue: Medical/Disease Research/Clinical Labs
New patents grants
-
Patent Title: Vidofludimus for use in the treatment or prevention of viral diseases Jul. 05, 2022
-
Patent Title: Il-17 and ifn-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation Apr. 05, 2022
Federal grants, loans, and purchases
Followers on IMUX's company Twitter account
Number of mentions of IMUX in WallStreetBets Daily Discussion
Recent insights relating to IMUX
Recent picks made for IMUX stock on CNBC
ETFs with the largest estimated holdings in IMUX
Flights by private jets registered to IMUX